
Steven Weitzman, MD
@drsweitzman1
MD Anderson faculty in Endocrine Neoplasia specializing in #ThyroidCancer, Thyroid nodules/biopsy, #Parathyroid, Pituitary, & Adrenal disease. Tweets are my own
ID: 809151418817015808
http://faculty.mdanderson.org/Steven_Weitzman/Default.asp 14-12-2016 21:41:46
175 Tweet
486 Followers
219 Following

My wonderful colleague Naifa Busaidy getting the #ATAThyroid2019 off to a great start discussing new developments and challenges in thyroidology. #endcancer



Amazing review by Michael Yeh at #ATAThyroid2019.

Fascinating work by #palliativecare MD Anderson Cancer Center. Self care is crucial to help providers in the fight to #endcancer.


Important look at patient reported outcomes for people with medullary #thyroidcancer. #endcancer. Julie A Sosa, MD Elizabeth Grubbs, MD




Vital work re: immunotherapy plus targeted therapy in anaplastic #thyroidcancer #endcancer tinyurl.com/y8vrk7q9 Maria Cabanillas, MD Ramona Dadu, MD Naifa Busaidy et al

Congratulations Mark Zafereo, MD. I am certain your leadership in this role will be impactful MD Anderson Cancer Center






👉A Phase 1b Study Evaluating the Safety and Efficacy of Sotorasib , a KRAS G12C Inhibitor, in Combination With Trametinib, a MEK Inhibitor, in KRAS p.G12C Mutated Solid Tumors Suresh S. Ramalingam, MD, FASCO #Targets21 in CRC and #NSCLC 🫁🧬


Do you have a friend or family member undergoing treatment MD Anderson Cancer Center? A great way to support them and other cancer patients is to donate blood. Give their name and they get $25 credit on their bill! #EndCancer


Use of T3 in the treatment of hypothyroidism remains a source of controversy. #endcancer Trisha Cubb MD liebertpub.com/doi/10.1089/ct…